

Doptelet® (avatrombopag) is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure or chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.¹

This resource lists codes that may be useful for identifying appropriate patients for Doptelet. It is important to note that the codes identified on the following pages are examples only. Each provider is responsible for all coding decisions and submitting complete and accurate information to the patient’s insurer. The use of the following codes does not guarantee coverage.

NATIONAL DRUG CODE (NDC) FOR DOPELET¹

Dosage	Carton Code	Blister Card Code
Carton of 1 blister card with 10 tablets	NDC 71369-020-10	NDC 71369-020-11
Carton of 1 blister card with 15 tablets	NDC 71369-020-15	NDC 71369-020-16
Carton of 2 blister cards, each with 15 tablets (30 tablets total)	NDC 71369-020-30	NDC 71369-020-16



For more information, call Doptelet Connect™ at 1-833-368-2663 Monday through Friday, 8 AM to 8 PM ET.

INDICATION

DOPELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with:

- Chronic liver disease who are scheduled to undergo a procedure.
- Chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Thrombotic/Thromboembolic Complications. DOPELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

Please see additional Important Safety Information throughout and full Prescribing Information for Doptelet at doptelethcp.com.

- Adult patients with chronic liver disease who are scheduled to undergo a procedure¹
- Adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment¹

PURPURA AND OTHER HEMORRHAGIC CONDITIONS²

ICD-10-CM	Description
D69.3 ● ●	Immune thrombocytopenic purpura
D69.49 ● ●	Other primary thrombocytopenia
D69.59 ● ●	Other secondary thrombocytopenia
D69.6 ● ●	Thrombocytopenia, unspecified

ALCOHOLIC LIVER DISEASES²

ICD-10-CM	Description	ICD-10-CM	Description
K70 ●	Alcoholic liver disease	K70.30 ●	Alcoholic cirrhosis of liver without ascites
K70.0 ●	Alcoholic fatty liver	K70.31 ●	Alcoholic cirrhosis of liver with ascites
K70.1 ●	Alcoholic hepatitis	K70.4 ●	Alcoholic hepatic failure
K70.10 ●	Alcoholic hepatitis without ascites	K70.40 ●	Alcoholic hepatic failure without coma
K70.11 ●	Alcoholic hepatitis with ascites	K70.41 ●	Alcoholic hepatic failure with coma
K70.2 ●	Alcoholic fibrosis and sclerosis of liver	K70.9 ●	Alcoholic liver disease, unspecified
K70.3 ●	Alcoholic cirrhosis of liver		

FDA=US Food and Drug Administration; ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification.

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Thrombotic/Thromboembolic Complications. (cont'd)

Consider the potential increased thrombotic risk when administering DOPELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.

Please see additional Important Safety Information throughout and full Prescribing Information for Doptelet at doptelethcp.com.

- Adult patients with chronic liver disease who are scheduled to undergo a procedure¹
- Adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment¹

TOXIC LIVER DISEASES ²			
ICD-10-CM	Description	ICD-10-CM	Description
K71 ●	Toxic liver disease	K71.5 ●	Toxic liver disease with chronic active hepatitis
K71.0 ●	Toxic liver disease with cholestasis	K71.50 ●	Toxic liver disease with chronic active hepatitis without ascites
K71.1 ●	Toxic liver disease with hepatic necrosis	K71.51 ●	Toxic liver disease with chronic active hepatitis with ascites
K71.10 ●	Toxic liver disease with hepatic necrosis, without coma	K71.6 ●	Toxic liver disease with hepatitis, not elsewhere classified
K71.11 ●	Toxic liver disease with hepatic necrosis, with coma	K71.7 ●	Toxic liver disease with fibrosis and cirrhosis of liver
K71.2 ●	Toxic liver disease with acute hepatitis	K71.8 ●	Toxic liver disease with other disorders of liver
K71.3 ●	Toxic liver disease with chronic persistent hepatitis	K71.9 ●	Toxic liver disease, unspecified
K71.4 ●	Toxic liver disease with chronic lobular hepatitis		

HEPATIC FAILURE NOT ELSEWHERE CLASSIFIED ²			
ICD-10-CM	Description	ICD-10-CM	Description
K72 ●	Hepatic failure not elsewhere classified	K72.10 ●	Chronic hepatic failure without coma
K72.0 ●	Acute and subacute hepatic failure	K72.11 ●	Chronic hepatic failure with coma
K72.00 ●	Acute and subacute hepatic failure without coma	K72.9 ●	Hepatic failure, unspecified
K72.01 ●	Acute and subacute hepatic failure with coma	K72.90 ●	Hepatic failure, unspecified without coma
K72.1 ●	Chronic hepatic failure	K72.91 ●	Hepatic failure, unspecified with coma

IMPORTANT SAFETY INFORMATION *(cont'd)*

WARNINGS AND PRECAUTIONS *(cont'd)*

Thrombotic/Thromboembolic Complications. *(cont'd)*

DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts and for signs and symptoms of thromboembolic events and institute treatment promptly.

Please see additional Important Safety Information throughout and full Prescribing Information for Doptelet at doptelethcp.com.

- Adult patients with chronic liver disease who are scheduled to undergo a procedure¹
- Adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment¹

CHRONIC HEPATITIS, NOT ELSEWHERE CLASSIFIED²

ICD-10-CM	Description	ICD-10-CM	Description
K73 ●	Chronic hepatitis, not elsewhere classified	K73.2 ●	Chronic active hepatitis, not elsewhere classified
K73.0 ●	Chronic persistent hepatitis, not elsewhere classified	K73.8 ●	Other chronic hepatitis, not elsewhere classified
K73.1 ●	Chronic lobular hepatitis, not elsewhere classified	K73.9 ●	Chronic hepatitis, unspecified

FIBROSIS AND CIRRHOSIS OF THE LIVER²

ICD-10-CM	Description	ICD-10-CM	Description
K74 ●	Fibrosis and cirrhosis of liver	K74.4 ●	Secondary biliary cirrhosis
K74.0 ●	Hepatic fibrosis	K74.5 ●	Biliary cirrhosis, unspecified
K74.1 ●	Hepatic sclerosis	K74.6 ●	Other and unspecified cirrhosis of liver
K74.2 ●	Hepatic fibrosis with hepatic sclerosis	K74.60 ●	Unspecified cirrhosis of liver
K74.3 ●	Primary biliary cirrhosis	K74.69 ●	Other cirrhosis of liver

OTHER INFLAMMATORY LIVER DISEASES²

ICD-10-CM	Description	ICD-10-CM	Description
K75 ●	Other inflammatory liver diseases	K75.4 ●	Autoimmune hepatitis
K75.0 ●	Abscess of liver	K75.8 ●	Other specified inflammatory liver diseases
K75.1 ●	Phlebitis of portal vein	K75.81 ●	Nonalcoholic steatohepatitis (NASH)
K75.2 ●	Nonspecific reactive hepatitis	K75.89 ●	Other specified inflammatory liver diseases
K75.3 ●	Granulomatous hepatitis, not elsewhere classified	K75.9 ●	Inflammatory liver disease, unspecified

IMPORTANT SAFETY INFORMATION (cont'd)

Serious Adverse Reactions

Serious adverse reaction that occurred more frequently in DOPTelet-treated patients with Chronic ITP (9%; 12/128) compared to placebo (5%; 1/22) was headache, occurring in 1.6% (2/128).

The most common serious adverse reaction reported in DOPTelet-treated patients with CLD compared to placebo was hyponatremia (0.7% v. 0%).

Please see additional Important Safety Information throughout and full Prescribing Information for Doptelet at doptelethcp.com.

- Adult patients with chronic liver disease who are scheduled to undergo a procedure¹
- Adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment¹

OTHER LIVER DISEASES ²			
ICD-10-CM	Description	ICD-10-CM	Description
K76 ●	Other diseases of liver	K76.6 ●	Portal hypertension
K76.0 ●	Fatty (change of) liver, not elsewhere classified	K76.7 ●	Hepatorenal syndrome
K76.1 ●	Chronic passive congestion of liver	K76.8 ●	Other specified diseases of liver
K76.2 ●	Central hemorrhagic necrosis of liver	K76.81 ●	Hepatopulmonary syndrome
K76.3 ●	Infarction of liver	K76.89 ●	Other specified diseases of liver
K76.4 ●	Peliosis hepatis	K76.9 ●	Liver disease, unspecified
K76.5 ●	Hepatic veno-occlusive disease		

LIVER DISORDERS IN DISEASES CLASSIFIED ELSEWHERE ²	
ICD-10-CM	Description
K77 ●	Liver disorders in diseases classified elsewhere

CHRONIC VIRAL HEPATITIS ²			
ICD-10-CM	Description	ICD-10-CM	Description
B18 ●	Chronic viral hepatitis	B18.2 ●	Chronic viral hepatitis C
B18.0 ●	Chronic viral hepatitis B with delta-agent	B18.8 ●	Other chronic viral hepatitis
B18.1 ●	Chronic viral hepatitis B without delta-agent	B18.9 ●	Chronic viral hepatitis, unspecified

IMPORTANT SAFETY INFORMATION (cont'd)

Adverse Reactions

The most common adverse reactions (≥3%) in patients with chronic liver disease were pyrexia, abdominal pain, nausea, headache, fatigue, and peripheral edema.

Please see additional Important Safety Information throughout and full Prescribing Information for Doptelet at doptelethcp.com.

- Adult patients with chronic liver disease who are scheduled to undergo a procedure¹
- Adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment¹

MALIGNANT NEOPLASMS OF THE LIVER AND INTRAHEPATIC BILE DUCTS²

ICD-10-CM	Description	ICD-10-CM	Description
C22.0	● Malignant neoplasms of liver and intrahepatic bile ducts	C22.4	● Other carcinomas of liver
C22.1	● Intrahepatic bile duct carcinoma	C22.7	● Other specified conditions of liver
C22.2	● Hepatoblastoma	C22.8	● Malignant neoplasm of liver primary
C22.3	● Angiosarcoma of liver	C22.9	● Malignant neoplasm of liver, not specified

SECONDARY MALIGNANT NEOPLASM OF THE LIVER AND INTRAHEPATIC BILE DUCT²

ICD-10-CM	Description
C78.7	● Secondary malignant neoplasm of liver and intrahepatic bile duct

References: 1. DOPTelet (avatrombopag) [prescribing information]. Durham, NC: AkaRx, Inc; 2021. 2. 2022 ICD-10-CM. Centers for Medicare & Medicaid Services website. Accessed April 3, 2024. <https://www.cms.gov/medicare/coding-billing/icd-10-codes/2022-icd-10-cm>

IMPORTANT SAFETY INFORMATION (cont'd)

Adverse Reactions (cont'd)

The most common adverse reactions (≥10%) in patients with chronic immune thrombocytopenia were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.

Postmarketing Experience

Following the approval of DOPTelet, hypersensitivity reactions involving the immune system, including, but not limited to, pruritus, rash, choking sensation, swollen face, and swollen tongue have been reported.

These are not all the possible risks associated with DOPTelet. Please see Full Prescribing Information for DOPTelet at doptelethcp.com

To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.

Please see full Prescribing Information for Doptelet at doptelethcp.com.